Abstract
In June of 2013 the American College of Cardiology and American Heart Association released a revised version of guidelines regarding the recommendations of HMG CoA reductase inhibitors (statins). Following this, the United States Preventive Services Task Force released its own set of guidelines regarding the use of statins in 2016. Both sets of guidelines included recommendations that differed significantly from previously established statin recommendations. However, the guidelines included several differences between the two sets. This article discusses both sets of guidelines and reviews the published literature analyzing the adoption of the new recommendations.
| Original language | American English |
|---|---|
| Journal | Oklahoma State Medical Proceedings |
| Volume | 1 |
| Issue number | 1 |
| State | Published - 16 Oct 2017 |